Table 3.

Effects of extended-release niacin and a combination of extended-release niacin and lovastatin, relative to placebo, on apoA-I-containing HDL subpopulation concentrations in the non-fasting state.

	Placebo	Niacin	Niacin+Lovastatin
preβ1	18.1±5.5	16.3±5.4	18.5±5.8
preβ2	2.7±1.1	3.0±1.0	3.2±1.6
α1	7.1±3.5	14.1±5.9*	13.5±3.7*
α2	27.0±5.6	33.5±2.2†	36.9±4.1*
α3	25.4±5.9	22.5±6.9	21.5±4.2
α4	11.8±1.7	10.2±2.0	9.1±0.7
preα1	2.4±2.1	7.8±5.1†	6.0±3.1
preα2	4.1±1.0	6.8±2.1†	6.6±2.0†
preα3	2.9±0.9	2.8±0.7	2.6±0.3
preα4	1.5±0.6	1.3±0.4	1.3±0.2
CETP	0.98±0.15	0.91±0.31	0.78±0.19
LCAT	11.0±1.5	9.6±1.5	10.2±1.8

HDL subpopulations expressed as mg/dL of apoA-I; CETP and LCAT mass expressed as μg/ml Values are mean±SD;

^*P<0.01 vs placebo;

^†P<0.03 vs placebo